- A manifestation of the reactivation of varicella zoster virus which, as a primary infection, produces chickenpox (varicella). Following initial infection, the virus remains latent in the dorsal root or cranial sensory ganglia until it reactivates, producing zooster.
- Zoster is characterized by a unilateral, painful, vesicular cutaneous eruption with a dermatomal distribution.
Recombinant zoster vaccine, adjuvanted
Dose & Route
- 0.5 mL single dose unit given IM.
- Reconstituted with the accompanying vial ofASO1B adjuvanted suspension component
Administration Schedule & Minimum Intervals
Dose Minimum Age
Dose 1……….50 years and older
Dose 2……….2 to 6 months after dose 1; minimum interval 4 weeks; repeat dose if administered too soon regardless of previous herpes zoster or history of zoster vaccine live (ZVL, Zostavax) vaccination
RZV is recommended for the prevention of herpes zoster and related complications for immunocompetent adults aged ≥ 50 years.
RZV is recommended for prevention of herpes zoster and related complications for immunocompetent adults who previously received zoster vaccine live (ZVL).
RZV may be used in adults aged ≥ is preferred over ZVL for the prevention of herpes zoster and related complications.
RZV may be used in adults aged ≥ 50 years irrespective of prior receipt of varicella vaccine or ZVL and does not require screening for a history of chickenpox (varicella).
- History of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX.
- Moderate or severe acute illness.
Consider delaying RZV until after pregnancy if RZV is otherwise indicated
Sever immunocompromising conditions (including HIV infection regardless of CD4 count**): 2-dose series recombinant zoster vaccine (RZV, Shingrix) 2-6 months apart; minimum interval 4 weeks; repeat dose if administered too soon.
If there is no documented history of varicella, varicella vaccination, or herpes zoster providers should refer to the clinical considerations for use of RZV in immunocompromised adults aged ≥ 19 years and the ACIP varicella vaccine recommendations for further guidance; Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 | MMWR (cdc.gov)
This vaccine is not a substitute for varicella vaccine and should never be administered to children.
Not indicated for treatment of herpes zoster (shingles) or postherpetic neuralgia
The duration of protection after vaccination is unknown.
RZV is stored in the refrigerator at 36˚F to 46˚F (2˚C to 8˚C)
After reconstitution, administer immediately or store refrigerated and use within 6 hours. Discard reconstituted vaccine if not used within 6 hours.